|
"zhu ax"的相关文件
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
| 國家衛生研究院 |
2018-01 |
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
|
Javle, M;Lowery, M;Shroff, RT;Weiss, KH;Springfeld, C;Borad, MJ;Ramanathan, RK;Goyal, L;Sadeghi, S;Macarulla, T;El-Khoueiry, A;Kelley, RK;Borbath, I;Choo, SP;Oh, DY;Philip, PA;Chen, LT;Reungwetwattana, T;Van Cutsem, E;Yeh, KH;Ciombor, K;Finn, RS;Patel, A;Sen, S;Porter, D;Isaacs, R;Zhu, AX;Abou-Alfa, GK;Bekaii-Saab, T |
| 國家衛生研究院 |
2016-08 |
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
|
Zhu, AX;Chen, D;He, W;Kanai, M;Voi, M;Chen, LT;Daniele, B;Furuse, J;Kang, YK;Poon, RT;Vogel, A;Chiang, DY |
| 國家衛生研究院 |
2014-07-02 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國家衛生研究院 |
2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
|
